Abstract
Myeloid malignancies frequently harbor specific mutations in protein tyrosine kinases leading to oncogenic cellsignaling. The most extensively investigated example is chronic myeloid leukemia, where the pathogenic tyrosine kinasefusion protein Bcr-Abl is a successful target for disease control by the specific inhibitor imatinib mesylate. In acute mye-loid leukemia the receptor tyrosine kinase Flt3 is frequently mutated and inhibitors to impair the oncogenic signaling arein development. In this review we exemplify oncogenic signaling and how signal pathways can be unraveled with helpfrom proteomics-based technologies. The distinction between cell extract and single cell approaches aiming at rigorousstandardization and reliable quantitative aspects for future proteomics-based diagnostics is discussed.
Keywords: Proteomics, biosignature, receptor tyrosine kinase (RTK), Flt3, Kit, PDGFR, Bcr-Abl, JAK2, cell signaling
Current Pharmaceutical Biotechnology
Title: Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies
Volume: 7 Issue: 3
Author(s): Eystein Oveland, Kari E. Fladmark, Line Wergeland, Bjorn Tore Gjertsen and Randi Hovland
Affiliation:
Keywords: Proteomics, biosignature, receptor tyrosine kinase (RTK), Flt3, Kit, PDGFR, Bcr-Abl, JAK2, cell signaling
Abstract: Myeloid malignancies frequently harbor specific mutations in protein tyrosine kinases leading to oncogenic cellsignaling. The most extensively investigated example is chronic myeloid leukemia, where the pathogenic tyrosine kinasefusion protein Bcr-Abl is a successful target for disease control by the specific inhibitor imatinib mesylate. In acute mye-loid leukemia the receptor tyrosine kinase Flt3 is frequently mutated and inhibitors to impair the oncogenic signaling arein development. In this review we exemplify oncogenic signaling and how signal pathways can be unraveled with helpfrom proteomics-based technologies. The distinction between cell extract and single cell approaches aiming at rigorousstandardization and reliable quantitative aspects for future proteomics-based diagnostics is discussed.
Export Options
About this article
Cite this article as:
Oveland Eystein, Kari E. Fladmark , Wergeland Line, Bjorn Tore Gjertsen and Hovland Randi, Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies, Current Pharmaceutical Biotechnology 2006; 7 (3) . https://dx.doi.org/10.2174/138920106777549696
DOI https://dx.doi.org/10.2174/138920106777549696 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection
Current Genomics Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Oncologists Current Opinion on the Treatment of Colon Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Current Cancer Drug Targets Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Editorial (Thematic Issue: Combined Cancer Therapy)
Current Pharmaceutical Design Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design